VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF)
Molecular Evidence (rationale) for VEGF targeted therapy in iMCD patients:
- “VEGF is frequently elevated in iMCD. VEGF, which promotes cell survival, angiogenesis, and vascular permeability, is often elevated in parallel with iMCD symptoms” (Blood 2014)
Case Reports of anti-VEGF therapy for iMCD patients:
Sirolimus (Rapamycin) is an mTOR inhibitor that blocks VEGF expression by inhibiting mTOR.
- To learn more about sirolimus as treatment for iMCD, please click here.
Clinical Trials targeting VEGF in iMCD:
No clinical trials targeting VEGF in iMCD patients have been conducted.